Dulaglutide
Fat LossFDA-approved weekly GLP-1 agonistEstablished
FDA-approved once-weekly GLP-1 Fc-fusion peptide (Trulicity) for type 2 diabetes and CV risk reduction in eligible T2D populations.
For research use only.
Key Facts
- CAS
- 923950-08-7
- Molecular Weight (MW)
- ~63 kDa (Fc fusion)
- Half-life
- ~5 days
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Once weekly
- Last updated
- 8/23/2026
- Targets
- GLP-1 receptor
Overview
FDA-approved once-weekly GLP-1 Fc-fusion peptide (Trulicity) for type 2 diabetes and CV risk reduction in eligible T2D populations.
Protocol
- Dosage Range
- 0.75–4.5 mg once weekly (labeled T2D range)
- Frequency
- Once weekly
- Cycle
- Long-term as prescribed
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Single-dose pen
Science
Mechanism of Action
Two GLP-1 analog sequences fused to an IgG4 Fc domain, slowing clearance and allowing weekly dosing.
Targets
GLP-1 receptor
Studies
- REWIND CVOT— Journal/year not available
Benefits
Weekly T2D therapyCV risk reduction in labeled populations
Potential Side Effects
- GI class effects
- Injection-site reactions
References
- Trulicity labelExternal link · Year —